Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Catheter Precision's operating assets for the quarter that ended in Mar. 2026 was $34.64 Mil. Catheter Precision's operating liabilities for the quarter that ended in Mar. 2026 was $13.93 Mil. Catheter Precision's Total Assets for the quarter that ended in Dec. 2025 was $15.86 Mil. Therefore, Catheter Precision's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 1.31.
Catheter Precision Scaled Net Operating Assets Related Terms
Catheter Precision Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Catheter Precision's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catheter Precision Scaled Net Operating Assets Chart
VTAK vs ALURD, BJDX, AMIX: Scaled Net Operating Assets Comparison
For the Medical Devices subindustry, Catheter Precision's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catheter Precision Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Catheter Precision's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Catheter Precision's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 1.31 mean?
Catheter Precision (VTAK) has a Scaled Net Operating Assets of 1.31 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Catheter Precision and its competitors.
Is Catheter Precision's Scaled Net Operating Assets too high?
Catheter Precision's current Scaled Net Operating Assets is 1.31. Overall, Catheter Precision has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Catheter Precision's Scaled Net Operating Assets compare to ALURD and BJDX?
Catheter Precision's Scaled Net Operating Assets of 1.31 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Catheter Precision and its competitors. Catheter Precision's current Scaled Net Operating Assets is 1.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catheter Precision stock overvalued right now?
Based on GuruFocus' analysis, Catheter Precision (VTAK) is currently considered Possible Value Trap. The stock's GF Value™ is $1.71, compared to a current price of $0.79 — trading 53.8% below its estimated fair value. The current Scaled Net Operating Assets is 1.31. Catheter Precision's overall GF Score™ is 23/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Catheter Precision (VTAK), the current Scaled Net Operating Assets is 1.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catheter Precision (VTAK) Overvalued in 2026?
Based on GuruFocus' analysis, Catheter Precision stock appears to be undervalued.
The current stock price of $0.79 is trading 53.8% below its estimated GF Value™ of $1.71.
GuruFocus considers Catheter Precision to be Possible Value Trap.
Key valuation signals for VTAK:
Scaled Net Operating Assets: 1.31
GF Value™: $1.71 vs. price of $0.79 (53.8% below fair value)
No single metric tells the full story. See the VTAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.
23GF Score
Get the complete analysis for VTAK
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VTAK has been successfully added to your 
